Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)

Maximilian Stahl, Jan Philipp Bewersdorf, Zhuoer Xie, Matteo Giovanni Della Porta, Rami Komrokji, Mina L. Xu, Omar Abdel-Wahab, Justin Taylor, David P. Steensma, Daniel T. Starczynowski, Mikkael A. Sekeres, Guillermo Sanz, David A. Sallman, Gail J. Roboz, Uwe Platzbecker, Mrinal M. Patnaik, Eric Padron, Olatoyosi Odenike, Stephen D. Nimer, Aziz NazhaRavi Majeti, Sanam Loghavi, Richard F. Little, Alan F. List, Tae Kon Kim, Christopher S. Hourigan, Robert P. Hasserjian, Stephanie Halene, Elizabeth A. Griffiths, Steven D. Gore, Peter Greenberg, Maria E. Figueroa, Pierre Fenaux, Fabio Efficace, Amy E. DeZern, Naval G. Daver, Jane E. Churpek, Hetty E. Carraway, Rena Buckstein, Andrew M. Brunner, Jacqueline Boultwood, Uma Borate, Rafael Bejar, John M. Bennett, Andrew H. Wei, Valeria Santini, Michael R. Savona, Amer M. Zeidan

Research output: Contribution to journalReview articlepeer-review

Abstract

The guidelines for classification, prognostication, and response assessment of myelodysplastic syndromes/neoplasms (MDS) have all recently been updated. In this report on behalf of the International Consortium for MDS (icMDS) we summarize these developments. We first critically examine the updated World Health Organization (WHO) classification and the International Consensus Classification (ICC) of MDS. We then compare traditional and molecularly based risk MDS risk assessment tools. Lastly, we discuss limitations of criteria in measuring therapeutic benefit and highlight how the International Working Group (IWG) 2018 and 2023 response criteria addressed these deficiencies and are endorsed by the icMDS. We also address the importance of patient centered care by discussing the value of quality-of-life assessment. We hope that the reader of this review will have a better understanding of how to classify MDS, predict clinical outcomes and evaluate therapeutic outcomes.

Original languageEnglish (US)
Article number101128
JournalBlood Reviews
Volume62
DOIs
StatePublished - Nov 2023

Keywords

  • Diagnostic criteria
  • IPSS-M
  • MDS
  • Myelodysplastic syndrome
  • Novel therapies
  • Risk classification

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)'. Together they form a unique fingerprint.

Cite this